Virologic response characteristics in chronic hepatitis B patients receiving initial entecavir therapy:a nationwide multicenter cross-sectional study
摘要
目的 采用高灵敏度实时荧光定量聚合酶链反应(quantitative real-time polymerase chain reaction,qPCR)技术评估恩替卡韦(entecavir,ETV)初治慢性乙型肝炎(chronic hepatitis B,CHB)患者低病毒血症(low-level viremia,LLV)的发生率及危险因素.方法 开展全国多中心横断面研究,研究采用分层整群抽样方式,覆盖全国七大地理区域中14个省市、39家三级甲等具有代表性的肝病或传染病医院.纳入在2020年1月1日至4月30日期间就诊的接受ETV治疗24~48周且按当地医院标准乙肝病毒脱氧核糖核酸(hepatitis B virus deoxyribonucleic acid,HBV DNA)转阴的CHB患者,本研究使用检测下限为10 IU/mL的qPCR重新检测血清HBV DNA水平.LLV定义为HBV DNA处于10~2 000 IU/mL.采用多因素logistic回归分析独立预测因素.结果 在1000例常规检测"转阴"患者中,41.8%(418/1 000)存在LLV.多因素分析确认:年龄<45 岁(OR=2.236,95%CI:1.701~2.940,P<0.01)、乙型肝炎病毒 e 抗原(hepatitis B virus early antigen,HBeAg)阳性(OR=3.821,95%CI:2.829~5.161,P<0.01)为 LLV 的独立危险因素.延长ETV疗程仅显示微弱保护效应(OR=0.980,P=0.029,95%CI:0.963~0.998),但该效应在HBeAg阳性亚组消失(P=0.068).结论 年龄<45岁和HBeAg阳性是发生LLV的关键风险因素.ETV延长治疗对HBeAg阳性患者保护作用有限,提示针对高危人群应早期更换治疗方案以及初始治疗时需慎重选择ETV.
Objective To assess the prevalence and risk factors of low-level viremia(LLV)in chronic hepatitis B(CHB)patients receiving initial entecavir(ETV)therapy using high-sensitivity quantitative real-time polymerase chain reaction(qPCR).Methods A national multicenter cross-sectional study was conducted.The study adopted stratified cluster sampling and covered 14 provinces and municipalities in seven major geographical regions across the country,involving 39 representative tertiary grade-A hospitals specializing in liver diseases or infectious diseases.Patients with chronic hepatitis B(CHB)who received entecavir(ETV)treatment for 24 to 48 weeks and achieved hepatitis B virus deoxyribonucleic acid(HBV DNA)negativity according to local hospital standards during the period from January 1 to April 30,2020 were included.Serum HBV DNA levels were retested by qPCR with a limit of detection of 10 IU/mL.LLV was defined as HBV DNA of 10-2 000 IU/mL.Multivariate logistic regression analysis was performed to identify independent risk factors.Results Among 1 000 patients with undetectable HBV DNA on routine testing,41.8%(418/1 000)had LLV.Multivariate analysis confirmed that age<45 years(OR=2.236,95%CI:1.701-2.940,P<0.01)and HBeAg positivity(OR=3.821,95%CI:2.829-5.161,P<0.01)were independent risk factors for LLV.Prolonged ETV treatment showed only a weak protective effect(OR=0.980,95%CI:0.963-0.998,P=0.029),whereas this effect was absent in the HBeAg-positive subgroup(P=0.068).Conclusion Age<45 years and HBeAg positivity are key risk factors for the occurrence of LLV.Prolonged ETV therapy offers limited protection in HBeAg-positive patients,suggesting that treatment should be modified early for high-risk populations and that ETV should be carefully selected for initial therapy.